VRTX:NSD-Vertex Pharmaceuticals Incorporated (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 246.72

Change

0.00 (0.00)%

Market Cap

USD 63.10B

Volume

1.37M

Avg Analyst Target

USD 264.95 (+7.39%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis:
Based on the Vertex Pharmaceuticals Incorporated stock forecasts from 12 analysts, the average analyst target price for Vertex Pharmaceuticals Incorporated is USD 264.95 over the next 12 months. Vertex Pharmaceuticals Incorporated’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Vertex Pharmaceuticals Incorporated is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Vertex Pharmaceuticals Incorporated’s stock price was USD 246.72. Vertex Pharmaceuticals Incorporated’s stock price has changed by -2.84% over the past week, -14.32% over the past month and +13.65% over the last year.

About

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their c ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

USD70.91B 8.97 6.88
MRNA Moderna Inc

N/A

USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.40B 3.79 1.55
RPRX Royalty Pharma plc

N/A

USD26.93B 26.81 14.86
SGEN Seagen Inc

N/A

USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

N/A

USD18.31B 43.41 4.62
ARGX argenx SE

N/A

USD16.90B N/A N/A
INCY Incyte Corporation

N/A

USD16.59B 17.54 21.87

ETFs Containing VRTX

Symbol Name Weight Mer Price(Change) Market Cap
UBIO ProShares UltraPro Nasdaq.. 6.52 % 0.95 %

N/A

USD0.02B
SMRN:XETRA Amundi Etf Istoxx Europe .. 0.00 % 0.55 %

N/A

USD0.01B
MVOL:LSE iShares VI Public Limited.. 0.00 % 0.35 %

N/A

USD3.63B
VMOM:LSE Vanguard Global Momentum .. 0.00 % 0.00 %

N/A

USD0.07B
MKTN:PA Amundi ETF iStoxx Europe .. 0.00 % 0.55 %

N/A

USD0.01B
IQQ0:F iShares VI Public Limited.. 0.00 % 0.35 %

N/A

USD3.63B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.46B
IQQ0:XETRA iShares Edge MSCI World M.. 0.00 % 0.35 %

N/A

USD3.63B
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

N/A

USD0.44B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.45B
SXR0:XETRA iShares VI Public Limited.. 0.00 % 0.35 %

N/A

USD0.11B
XDEB:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

N/A

USD0.65B
ZGEN:CA BMO MSCI Genomic Innovati.. 0.00 % 0.40 %

N/A

N/A
ZINN:CA BMO MSCI Innovation Index.. 0.00 % 0.40 %

N/A

N/A
ASPY ASYMshares® ASYMmetric 5.. 0.00 % 0.95 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.60 %

N/A

N/A
FBTU:LSE First Trust Global Funds .. 0.00 % 0.60 %

N/A

N/A
MINV:LSE iShares VI Public Limited.. 0.00 % 0.35 %

N/A

USD3.63B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

N/A

USD0.46B
BIGT:LSE Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

USD0.04B
RYH Invesco S&P 500 Equal Wei.. 0.00 % 0.40 %

N/A

USD0.90B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD8.57M
BTAL AGFiQ U.S. Market Neutral.. 0.00 % 2.53 %

N/A

USD0.12B
EUSA iShares MSCI USA Equal We.. 0.00 % 0.09 %

N/A

USD0.44B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

N/A

USD1.32B
IBB iShares Biotechnology ETF 0.00 % 0.45 %

N/A

USD7.49B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

N/A

USD0.07B
VLQ:CA Vanguard Global Liquidity.. 0.00 % 0.37 %

N/A

USD0.01B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.10B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
CACG Legg Mason ETF Investment.. 0.00 % 0.53 %

N/A

USD0.17B
BUL Pacer US Cash Cows Growth.. 0.00 % 0.60 %

N/A

USD8.86M
QRFT QRAFT AI-Enhanced U.S. La.. 0.00 % 0.75 %

N/A

USD0.01B
SPGP Invesco S&P 500 GARP ETF 0.00 % 0.36 %

N/A

USD0.83B
PYF-U:CA Purpose Fund Corp. - Purp.. 0.00 % 0.72 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.37B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.35% 96% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.35% 96% A 95% A
Trailing 12 Months  
Capital Gain 13.65% 95% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.65% 95% A 90% A-
Trailing 5 Years  
Capital Gain 108.93% 83% B 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 108.93% 83% B 82% B-
Average Annual (5 Year Horizon)  
Capital Gain 12.02% 59% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.02% 58% F 63% D
Risk Return Profile  
Volatility (Standard Deviation) 24.49% 95% A 63% D
Risk Adjusted Return 49.06% 85% B 76% C
Market Capitalization 63.10B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 27.38 23% F 30% F
Price/Book Ratio 5.65 12% F 14% F
Price / Cash Flow Ratio 23.87 3% F 13% F
EV/EBITDA 17.74 10% F 30% F
Management Effectiveness  
Return on Equity 24.93% 97% A+ 89% B+
Return on Invested Capital 25.48% 94% A 91% A-
Return on Assets 13.79% 98% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.98 75% C 64% D
Short Percent 1.34% 80% B- 68% D+
Beta 0.61 81% B- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.